KYMR Kymera Therapeutics, Inc.
Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1815442 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY133.8%
TTM net income YoY-18.4%
TTM EPS YoY-1.1%
Revenue 3-yr CAGR29.7%
Net income 3-yr CAGR—
Margins
Gross margin0.0%
Operating margin-396.0%
Net margin-341.8%
FCF margin-282.6%
EBITDA margin-388.9%
Returns
ROE-27.3%
ROA-24.4%
ROIC (approx.)-30.8%
Asset turnover0.07x
Leverage & solvency
Liabilities / assets8.6%
Debt / equity0.00x
Current ratio11.13x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.82x
Accruals ratio-4.3%
Payout ratio—
Capex / revenue1.3%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $0 | $65.00M | $34.37M | $2.87M | $2.76M | $11.48M | $22.10M | $7.39M |
| Cost of revenue | $0 | $65.00M | $34.37M | $2.87M | $2.76M | $11.48M | $22.10M | $7.39M |
| Gross profit | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| R&D expense | $128.51M | $119.48M | $98.16M | $83.83M | $74.09M | $78.39M | $80.25M | $71.82M |
| SG&A expense | $18.72M | $21.13M | $20.36M | $16.93M | $17.34M | $17.64M | $16.27M | $16.33M |
| Operating income | -$147.23M | -$75.61M | -$84.15M | -$97.90M | -$92.52M | -$84.56M | -$74.43M | -$80.75M |
| Net income | -$132.00M | -$61.21M | -$69.23M | -$86.98M | -$82.17M | -$76.61M | -$65.58M | -$70.75M |
| EBITDA | -$145.63M | -$74.01M | -$82.13M | -$95.86M | -$90.82M | -$82.86M | -$72.38M | -$78.77M |
| EPS (basic) | -1.32 | -0.62 | -0.71 | — | -0.94 | -0.95 | -0.82 | — |
| EPS (diluted) | -1.32 | -0.62 | -0.71 | — | -0.94 | -0.95 | -0.82 | — |
| Weighted avg. shares (diluted) | 100.10M | 98.18M | 97.53M | — | 87.30M | 80.45M | 80.15M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $373.37M | $124.48M | $144.09M | $357.01M | $112.95M | $335.82M | $89.97M | $120.26M |
| Short-term investments | $597.84M | $566.51M | $506.84M | $491.26M | $392.73M | $329.63M | $373.18M | $368.49M |
| Receivables | — | $20.00M | — | $0 | — | $40.00M | — | $0 |
| Current assets | $998.59M | $737.26M | $677.43M | $871.21M | $528.30M | $728.33M | $500.95M | $510.27M |
| PP&E, net | $38.24M | $39.97M | $41.62M | $43.17M | $45.13M | $48.57M | $49.17M | $50.46M |
| Total assets | $1.77B | $1.65B | $1.67B | $1.74B | $1.10B | $1.13B | $918.31M | $978.03M |
| Current liabilities | $89.72M | $71.33M | $62.64M | $83.21M | $71.58M | $87.54M | $58.99M | $67.77M |
| Total liabilities | $152.74M | $136.19M | $129.38M | $163.15M | $155.79M | $159.59M | $132.08M | $142.42M |
| Shareholders' equity | $1.61B | $1.51B | $1.54B | $1.58B | $946.26M | $971.48M | $786.23M | $835.62M |
| Shares outstanding | 85.33M | 82.79M | 82.18M | 81.32M | 71.74M | 70.56M | 65.11M | 64.89M |
| Cash flow statement | ||||||||
| Operating cash flow | -$77.91M | -$54.06M | -$88.84M | -$66.75M | -$27.11M | -$59.88M | -$79.15M | -$61.78M |
| Capital expenditure | $315,000 | $473,000 | $434,000 | $106,000 | $181,000 | $695,000 | $467,000 | $936,000 |
| Free cash flow | -$78.23M | -$54.54M | -$89.27M | -$66.85M | -$27.29M | -$60.58M | -$79.62M | -$62.72M |
| Investing cash flow | $101.63M | $20.05M | -$142.84M | -$394.40M | -$235.30M | $60.02M | $48.62M | $68.57M |
| Financing cash flow | $225.57M | $14.42M | $18.77M | $705.22M | $39.51M | $245.73M | $258,000 | $2.77M |
| Depreciation & amortization | $1.60M | $1.60M | $2.02M | $2.03M | $1.70M | $1.70M | $2.05M | $1.99M |
| Stock-based compensation | $18.84M | $18.94M | $16.01M | $14.45M | $15.80M | $15.41M | $14.23M | $13.80M |
Free plan shows the latest 8 periods; Pro shows all 29 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.